Recent progress in development of siRNA delivery vehicles for cancer therapy

Advanced Drug Delivery Reviews

Volumn 104, Issue , 2016, Pages 61-77

  Kim, Hyun Jin ^a   Kim, Ahram ^b   Miyata, Kanjiro ^a   Kataoka, Kazunori ^a,b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION   (Japan)

Author keywords

Cancer therapy; Polyion complex micelle; RNAi; siRNA delivery; Systemic administration

Indexed keywords

DISEASES; NANOPARTICLES; NUCLEIC ACIDS; ONCOLOGY; RNA; VEHICLES;

CANCER THERAPY; POLYION COMPLEX MICELLES; RNAI; SIRNA DELIVERY; SYSTEMIC ADMINISTRATION;

GENE THERAPY;

ALN TTR 01; ALN TTR 02; ALN VSP 02; APN 401; ARGINYLGLYCYLASPARTIC ACID; ATU 027; CALAA 01; CALCIUM PHOSPHATE; CISPLATIN; DENDRIMER; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; GEMCITABINE; GLUTATHIONE; GOLD NANOPARTICLE; MACROGOL; POLYETHYLENEIMINE; POLYMER; POVIDONE; SILICON DIOXIDE; SMALL INTERFERING RNA; TKM 080301; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VINTAFOLIDE; NANOPARTICLE;

ADVANCED CANCER; AMYLOIDOSIS; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; ENDOSOME; EX VIVO GENE TRANSFER; FATIGUE; GENE SILENCING; HUMAN; HYDROPHOBICITY; IMMUNOGENICITY; LIVER CANCER; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; METASTATIC MELANOMA; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SOLID TUMOR; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ANIMAL; GENETICS; NEOPLASM;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; POLYMERS; RNA, SMALL INTERFERING;

EID: 84996644373     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.06.011     Document Type: Review

References (196)

1. [1] Wilson, R.C., Doudna, J.A., Molecular mechanism of RNA interference. Annu. Rev. Biophys. 42 (2013), 217–239.
2. [2] Lam, J., Chow, M., Zhang, Y., Leung, S., siRNA versus miRNA as therapeutics for gene silencing. Mol. Ther. Nucleic Acids, 4, 2015, e252.
3. [3] Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998), 806–811.
4. [4] Jinek, M., Doudna, J.A., A three-dimensional view of the molecular machinery of RNA inference. Nature 457 (2009), 405–412.
5. [5] Fellmann, C., Lowe, S.W., Stable RNA interference rules for silencing. Nat. Cell Biol. 16 (2014), 10–18.
6. [6] Davidson, B.L., McCray, P.B. Jr., Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12 (2011), 329–340.
7. [7] Wu, S.Y., Lopez-Berestein, G., Calin, G.A., Sood, A.K., RNAi therapies: drugging the undruggable. Sci. Transl. Med., 6, 2014, 240ps7.
8. [8] Landen, C.N. Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M.T., Lopez-Berestein, G., Sood, A.K., Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65 (2005), 6910–6918.
9. [9] Davis, M.E., Zuckerman, J.E., Choi, C.H.J., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D., Ribas, A., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464 (2010), 1067–1071.
10. [10] Khvalevsky, E.Z., Gabai, R., Rachmut, I.H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A.J., Yavin, E., Giladi, H., Rivkin, L., Simerzin, A., Eliakim, R., Khalaileh, A., Hubert, A., Lahav, M., Kopelman, Y., Goldin, E., Dancour, A., Hants, Y., Arbel-Alon, S., Abramovitch, R., Shemi, A., Galun, E., Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 20723–20728.
11. [11] Schultheis, B., Strumberg, D., Vank, A.C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., Drevs, J., First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J. Clin. Oncol. 32 (2014), 4141–4148.
12. [12] Tabernero, J., Shapiro, G.I., LoRusso, P.M., Cervantes, A., Schwartz, G.K., Weiss, G.J., Paz-Ares, L., Cho, D.C., Infante, J.R., Alsina, M., Gounder, M.M., Falzone, R., Harrop, J., White, A.C.S., Toudjarska, I., Bumcrot, D., Meyers, R.E., Hinkle, G., Svrzikapa, N., Hutabarat, R.M., Clausen, V.A., Cehelsky, J., Nochur, S.V., Gamba-Vitalo, C., Vaishnaw, A.K., Sah, D.W.Y., Gollob, J.A., Burris, H.A. III, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3 (2013), 406–417.
13. [13] Zuckerman, J.E., Choi, C.H.J., Han, H., Davis, M.E., Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 3137–3142.
14. [14] Naeye, B., Deschout, H., Caveliers, V., Descamps, B., Braeckmans, K., Vanhove, C., Demeester, J., Lahoutte, T., De Smedt, S.C., Raemdonck, K., In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials 34 (2013), 2350–2358.
15. [15] Christie, R.J., Matsumoto, Y., Miyata, K., Nomoto, T., Fukushima, S., Osada, K., Halnaut, J., Pittella, F., Kim, H.J., Nishiyama, N., Kataoka, K., Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 6 (2012), 5174–5189.
16. [16] Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P.N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., Munisamy, M., Falzone, R., Harrop, J., Cehelsky, J., Bettencourt, B.R., Geissler, M., Butler, J.S., Sehgal, A., Meyers, R.E., Chen, Q., Borland, T., Hutabarat, R.M., Clausen, V.A., Alvarez, R., Fitzgerald, K., Gamba-Vitalo, C., Nochur, S.V., Vaishnaw, A.K., Sah, D.W.Y., Gollob, J.A., Suhr, O.B., Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369 (2013), 819–829.
17. [17] Semple, S.C., Akinc, A., Chen, J., Sandhu, A.P., Mui, B.L., Cho, C.K., Sah, D.W.Y., Stebbing, D., Crosley, E.J., Yaworski, E., Hafez, I.M., Dorkin, J.R., Qin, J., Lam, K., Rajeev, K.G., Wong, K.F., Jeffs, L.B., Nechev, L., Eisenhardt, M.L., Jayaraman, M., Kazem, M., Maier, M.A., Srinivasulu, M., Weinstein, M.J., Chen, Q., Alvarez, R., Barros, S.A., De, S., Klimuk, S.K., Borland, T., Kosovrasti, V., Cantley, W.L., Tam, Y.K., Manoharan, M., Ciufolini, M.A., Tracy, M.A., Fougerolles, A., MacLachlan, I., Cullis, P.R., Madden, T.D., Hope, M.J., Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28 (2010), 172–176.
18. [18] Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V., Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., Giese, K., Klippel, A., Kaufmann, J., A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13 (2006), 1222–1234.
19. [19] Bartlett, D.W., Davis, M.E., Physiochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 18 (2007), 456–468.
20. [20] Zuckerman, J.E., Gritli, I., Tolcher, A., Heidel, J.D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M.E., Yen, Y., Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 11449–11454.
21. [21] Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I.E., Vogel, C.L., Burris, H.A. III, LoRusso, P.M., Yi, J.H., Saad, O., Tong, B., Chu, Y.W., Holden, S., Joshi, A., Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 69 (2012), 1229–1240.
22. [22] Plummer, R., Wilson, R.H., Calvert, H., Boddy, A.V., Griffin, M., Sludden, J., Tilby, M.J., Eatock, M., Pearson, D.G., Ottley, C.J., Matsumura, Y., Kataoka, K., Nishiya, T., A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104 (2011), 593–598.
23. [23] Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A., Davis, M.E., Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 15549–15554.
24. [24] Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M.R., Miyazono, K., Uesaka, M., Nishiyama, N., Kataoka, K., Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6 (2011), 815–823.
25. [25] Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D., Delivery materials for siRNA therapeutics. Nat. Mater. 12 (2013), 967–977.
26. [26] Choi, H.S., Liu, W., Misra, P., Tanaka, E., Zimmer, J.P., Itty Ipe, B., Bawendi, M.G., Frangioni, J.V., Renal clearance of quantum dots. Nat. Biotechnol. 25 (2007), 1165–1170.
27. [27] Schroeder, A., Levins, C.G., Cortez, C., Langer, R., Anderson, D.G., Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med. 267 (2010), 9–21.
28. [28] Gao, S., Dagnaes-Hansen, F., Nielsen, E.J.B., Wengel, J., Besenbacher, F., Howard, K.A., Kjems, J., The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17 (2009), 1225–1233.
29. [29] Turner, J.J., Jones, S.W., Moschos, S.A., Lindsay, M.A., Gait, M.J., MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol. BioSyst. 3 (2007), 43–50.
30. [30] Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986), 6387–6392.
31. [31] Cabral, H., Makino, J., Matsumoto, Y., Mi, P., Wu, H., Nomoto, T., Toh, K., Yamada, N., Higuchi, Y., Konishi, S., Kano, M.R., Nishihara, H., Miura, Y., Nishiyama, N., Kataoka, K., Systemic targeting of lymph node metastasis through the blood vascular system by using size-controlled nanocarriers. ACS Nano 9 (2015), 4957–4967.
32. [32] Sykes, E.A., Chen, J., Zheng, G., Chan, W.C.W., Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency. ACS Nano 8 (2014), 5696–5706.
33. [33] Zhu, X., Xu, Y., Solis, L.M., Tao, W., Wang, L., Behrens, C., Xu, X., Zhao, L., Liu, D., Wu, J., Zhang, N., Wistuba, I.I., Farokhazad, O.C., Zetter, B.R., Shi, J., Long-circulating siRNA nanoparticles for validating prohibitin1-targeted non-small cell lung cancer treatment. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 7779–7784.
34. [34] Kano, M.R., Nanotechnology and tumor microcirculation. Adv. Drug Deliv. Rev. 74 (2014), 2–11.
35. [35] Hansen, A.E., Petersen, A.L., Henriksen, J.R., Berresen, B., Rasmussen, P., Elema, D.R., Rosenschöld, P.M., Kristensen, A.T., Kjær, A., Andresen, T.L., Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper-64 liposomes. ACS Nano 9 (2015), 6985–6995.
36. [36] Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D.A., Torchilin, V.P., Jain, R.K., Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995), 3752–3756.
37. [37] Cabral, H., Murakami, M., Hojo, H., Terada, Y., Kano, M.R., Chung, U.–.I., Nishiyama, N., Kataoka, K., Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 11397–11402.
38. [38] Maeda, H., Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91 (2015), 3–6.
39. [39] Arrieta, Ó., Medina, L.A., Estrada-Lobato, E., Hernández-Pedro, N., Villanueva-Rodríguez, G., Martínez-Barrera, L., Macedo, E.O., López-Rodríquez, V., Motola-Kuba, D., Corona-Cruz, J.F., First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br. J. Cancer 106 (2012), 1027–1032.
40. [40] Nicholas, J.W., Bae, Y.H., EPR: evidence and fallacy. J. Control. Release 190 (2014), 451–464.
41. [41] Marina, N.M., Cochrane, D., Harney, E., Zomorodi, K., Blaney, S., Winick, N., Bernstein, M., Link, M.P., Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (doxil) in children with solid tumos: a pediatric oncology group study. Clin. Cancer Res. 8 (2002), 413–418.
42. [42] Hubert, A., Lyass, O., Pode, D., Gabizon, A., Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anti-Cancer Drugs 11 (2000), 123–127.
43. [43] Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N.I., Lotem, M., Brufman, G., Gabizon, A., Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89 (2000), 1037–1047.
44. [44] Boers-Sonderen, M.J., van Herpen, C.M., van der Graaf, W.T., Desar, I.M., van der Logt, M.G., de Beer, Y.M., Ottevanger, P.B., van Erp, N.P., Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). Cancer Chemother. Pharmacol. 74 (2014), 457–463.
45. [45] Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E., Gabizon, A.A., Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86 (1999), 72–78.
46. [46] Lammers, T., Kiessling, F., Hennink, W.E., Storm, G., Drug targeting to tumors: principles, pitfalls, and (pre-) clinical progress. J. Control. Release 161 (2012), 175–187.
47. [47] Bae, Y.H., Park, K., Targeted drug delivery to tumors: myths, reality, and possibility. J. Control. Release 153 (2011), 198–205.
48. [48] Taurin, S., Nehoff, H., Greish, K., Anticancer nanomedicine and tumor vascular permeability; where is the missing link?. J. Control. Release 164 (2012), 265–275.
49. [49] Matsumoto, Y., Nichols, J.W., Toh, K., Nomoto, T., Cabral, H., Miura, Y., Christie, R.J., Yamada, N., Ogura, T., Kano, M.R., Matsumura, Y., Nishiyama, N., Yamasoba, T., Bae, Y.H., Kataoka, K., Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nanotechol., 2016.
50. [50] Chauhan, V.P., Jain, R.K., Strategies for advancing cancer nanomedicine. Nat. Mater. 12 (2013), 958–962.
51. [51] Smith, N.R., Baker, D., Farren, M., Pommier, A., Swann, R., Wang, X., Mistry, S., McDaid, K., Kendrew, J., Womack, C., Wedge, S.R., Barry, S.T., Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin. Cancer Res. 19 (2013), 6943–6956.
52. [52] Perrault, S.D., Walkey, C., Jennings, T., Fischer, H.C., Chan, W.C., Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9 (2009), 1909–1915.
53. [53] Popović, Z., Liu, W., Chauhan, V.P., Lee, J., Wong, C., Greytak, A.B., Insin, N., Nocera, D.G., Fukumura, D., Jain, R.K., Bawendi, M.G., A nanoparticle size series for in vivo fluorescence imaging. Angew. Chem. Int. Ed. 49 (2010), 8649–8652.
54. [54] Jain, R.K., Martin, J.D., Stylianopoulos, T., The role of mechanical forces in tumor growth and therapy. Annu. Rev. Biomed. Eng. 16 (2014), 321–346.
55. [55] Kano, M.R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., Hirakawa, K., Ouchi, Y., Nishiyama, N., Kataoka, K., Miyazono, K., Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 3460–3465.
56. [56] Mckee, T.D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J.P., Bawendi, M.G., Boucher, Y., Breakefield, X.O., Jain, R.K., Degradation of fibrillary collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66 (2006), 2509–2513.
57. [57] Kanwar, Y.S., Farquhar, M.G., Presence of heparan sulfate in the glomerular basement membrane. Proc. Natl. Acad. Sci. U. S. A. 76 (1979), 1303–1307.
58. [58] Soji, T., Murata, Y., Ohira, A., Nishizono, H., Tanaka, M., Herbert, D.C., Evidence that hepatocytes can phagocytize exogenous substances. Anat. Rec. 233 (1992), 543–546.
59. [59] Elvevold, K., Smedsrød, B., Martinez, I., The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity. Am. J. Physiol. Gastrointest. Liver Physiol. 294 (2008), G391–G400.
60. [60] Gustafson, H.H., Holt-Casper, D., Grainger, D.W., Ghandehari, H., Nanoparticle uptake: the phagocyte problem. Nano Today 10 (2015), 487–510.
61. [61] Braeckmans, K., Buyens, K., Bouquet, W., Vervaet, C., Joye, P., De Vos, F., Plawinski, L., Doeuvre, L., Angles-Cano, E., Sanders, N.N., Demeester, J., De Smedt, S.C., Sizing nanomatter in biological fluids by fluorescence single particle tracking. Nano Lett. 10 (2010), 4435–4442.
62. [62] Akinc, A., Battaglia, G., Exploiting endocytosis for nanomedicines. Cold Spring Harb. Perspect. Biol., 5, 2013, a016980.
63. [63] Pelegri-O'Day, E.M., Lin, E.–.W., Maynard, H.D., Therapeutic protein-polymer conjugates: advancing beyond PEGylation. J. Am. Chem. Soc. 136 (2014), 14323–14332.
64. [64] Knop, K., Hoogenboom, R., Fischer, D., Schubert, U.S., Poly(ethylene glycol) in drug delivery:pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 49 (2010), 6288–6308.
65. [65] Qi, Y., Chilkoti, A., Protein-polymer conjugation-moving beyond PEgylation. Curr. Opin. Chem. Biol. 28 (2015), 181–193.
66. [66] Barenholz, Y., Doxil®-the first FDA-approved nano-drug: lessons learned. J. Control. Release 160 (2012), 117–134.
67. [67] Pérez-Herrero, E., Fernández-Medarde, A., Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93 (2015), 52–79.
68. [68] Schellekens, H., Hennink, W.E., Brinks, V., The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 30 (2013), 1729–1734.
69. [69] Longo, N., Harding, C.O., Burton, B.K., Grange, D.K., Vockley, J., Wasserstein, M., Rice, G.M., Dorenbaum, A., Neuenburg, J.K., Musson, D.G., Gu, Z., Sile, S., Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicenter, phase 1 dose-escalation trial. Lancet 384 (2014), 37–44.
70. [70] Yang, Q., Lai, S.K., Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7 (2015), 655–677.
71. [71] Armstrong, J.K., Hempel, G., Koling, S., Chan, L.S., Fisher, T., Meiselman, H.J., Garratty, G., Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110 (2007), 103–111.
72. [72] Beddoes, C.M., Case, C.P., Briscoe, W.H., Understanding nanoparticle cellular entry: A physicochemical perspective. Adv. Colloid Interf. Sci. 218 (2015), 48–68.
73. [73] Canton, I., Battaglia, G., Endocytosis at the nanoscale. Chem. Soc. Rev. 41 (2012), 2718–2739.
74. [74] Venkataraman, S., Hedrick, J.L., Ong, Z.Y., Yang, C., Ee, P.L., Hammond, P.T., Yang, Y.Y., The effects of polymeric nanostructure shape on drug delivery. Adv. Drug Deliv. Rev. 63 (2011), 1228–1246.
75. [75] Trono, J.D., Mizuno, K., Yusa, N., Matsukawa, T., Yokoyama, K., Uesaka, M., Size, concentration and incubation time dependence of gold nanoparticle uptake into pancreas cancer cells and its future application to X-ray drug delivery system. J. Radiat. Res. 52 (2011), 103–109.
76. [76] Chithrani, D.B., Intracellular uptake, transport, and processing of gold nanostructures. Mol. Membr. Biol. 27 (2010), 299–311.
77. [77] Gao, H., Shi, W., Freund, L.B., Mechanics of receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 9469–9474.
78. [78] Rehman, Z.U., Zuhorn, I.S., Hoekstra, D., How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances. J. Control. Release 166 (2013), 46–56.
79. [79] Itaka, K., Kataoka, K., Recent development of nonviral gene delivery systems with virus-like structures and mechanism. Eur. J. Pharm. Biopharm. 71 (2009), 475–483.
80. [80] Bertrand, N., Wu, J., Xu, X., Kamaly, N., Farokhzad, O.C., Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66 (2014), 2–25.
81. [81] Zhong, Y., Meng, F., Deng, C., Zhong, Z., Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules 15 (2014), 1955–1969.
82. [82] Temming, K., Schiffelers, R.M., Molema, G., Kok, R.J., RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature. Drug Resist. Updat. 8 (2005), 381–402.
83. [83] Sutherland, M., Gordon, A., Shnyder, S.D., Patterson, L.H., Sheldrake, H.M., RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects against bone metastasis. Cancers 4 (2012), 1106–1145.
84. [84] Sancey, L., Garanger, E., Foilard, S., Schoehn, G., Hurbin, A., Albiges-Rizo, C., Boturyn, D., Souchier, C., Grichine, A., Dumy, P., Coll, J.L., Clustering and internalization of integrin αvβ3 with a tetrameric RGD-synthetic peptide. Mol. Ther. 17 (2009), 837–843.
85. [85] Trapani, G., Denora, N., Trapani, A., Laquintana, V., Recent advances in ligand targeted therapy. J. Drug Target. 20 (2012), 1–22.
86. [86] Tiller, K.E., Tessier, P.M., Advances in antibody design. Annu. Rev. Biomed. Eng. 17 (2015), 191–216.
87. [87] Peters, C., Brown, S., Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep., 35, 2015, e00225.
88. [88] Zhang, N., Liu, L., Dumitru, C.D., Cummings, N.R., Cukan, M., Jiang, Y., Li, Y., Li, F., Mitchell, T., Mallem, M.R., Ou, Y., Patel, R.N., Vo, K., Wang, H., Burnina, I., Choi, B.-K., Huber, H., Stadheim, T.A., Zha, D., Glycoengineered pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. mAbs 3 (2011), 289–298.
89. [89] Elmlund, L., Kӓck, C., Aastrup, T., Nicholls, I.A., Study of the interaction of trastuzumab and SKOV3 eptithelial cancer cells using a quartz crystal microbalance sensor. Sensors 15 (2015), 5884–5894.
90. [90] Tong, H., Zhang, L., Kaspar, A., Rames, M.J., Huang, L., Woodnutt, G., Ren, G., Peptide-conjugation induced conformational changes in human IgG1 observed by optimized negative-staining and individual-particle electron tomography. Sci. Rep., 3, 2013, 1089.
91. [91] van der Meel, R., Vehmeijer, L.J., Kok, R.J., Storm, G., van Gaal, E.V., Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev. 65 (2013), 1284–1298.
92. [92] Reddy, J.A., Dorton, R., Westrick, E., Dawson, A., Smith, T., Xu, L.-C., Vetzel, M., Kleindl, P., Vlahov, I.R., Leamon, C.P., Preclinical evaluation of EC145, a folate-Vinca alkaloid conjugate. Cancer Res. 67 (2007), 4434–4442.
93. [93] Naumann, R.W., Coleman, R.L., Burger, R.A., Sausville, E.A., Kutarska, E., Ghamande, S.A., Gabrail, N.Y., DePasquale, S.E., Nowara, E., Gilbert, L., Gersh, R.H., Teneriello, M.G., Harb, W.A., Konstantinopoulos, P.A., Penson, R.T., Symnowski, J.T., Lovejoy, C.D., Leamon, C.P., Morgenstern, D.E., Messmann, R.A., Precedent: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patient with platinum-resistant ovarian cell. J. Clin. Oncol. 31 (2013), 4400–4406.
94. [94] Park, K., Facing the truth about nanotechnology in drug delivery. ACS Nano 7 (2013), 7442–7447.
95. [95] Mindell, J.A., Lysosomal acidification mechanisms. Annu. Rev. Physiol. 74 (2012), 69–86.
96. [96] Appelqvist, H., Wäster, P., Kågedal, K., Öllinger, K., The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell Biol. 5 (2013), 214–226.
97. [97] Höbel, S., Aigner, A., Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 (2013), 484–501.
98. [98] Miyata, K., Oba, M., Nakanishi, M., Fukushima, S., Yamasaki, Y., Koyama, H., Nishiyama, N., Kataoka, K., Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. J. Am. Chem. Soc. 130 (2008), 16287–16294.
99. [99] Behr, J.P., The proton sponge: a trick to enter cells the viruses did not exploit. Chimia 51 (1997), 34–36.
100. [100] Sonawane, N.D., Szoka, F.C., Verkman, A.S., Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine–DNA polyplexes. J. Biol. Chem. 278 (2003), 44826–44831.
101. [101] Miyata, K., Nishiyama, N., Kataoka, K., Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses. Chem. Soc. Rev. 41 (2012), 2562–2574.
102. [102] Rao, N.M., Cationic lipid-mediated nucleic acid delivery: beyond being cationic. Chem. Phys. Lipids 163 (2010), 245–252.
103. [103] Kataoka, K., Harada, A., Nagasaki, Y., Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47 (2001), 113–131.
104. [104] Dong, Y., Love, K.T., Dorkin, J.R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R.L., Yin, H., Chen, Y., Vegas, A.J., Alabi, C.A., Sahay, G., Olejnik, K.T., Wang, W., Schroeder, A., Lytton-Jean, A.K.R., Siegwart, D.J., Akinc, A., Barnes, C., Barros, S.A., Carioto, M., Fitzgerald, K., Hettinger, J., Kumar, V., Novobrantseva, T.I., Qin, J., Querbes, W., Koteliansky, V., Langer, R., Anderson, D.G., Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 3955–3960.
105. [105] Schaffert, D., Troiber, C., Salcher, E.E., Fröhlich, T., Martin, I., Badgujar, N., Dohmen, C., Edinger, D., Kläger, R., Maiwald, G., Farkasova, K., Seeber, S., Jahn-Hofmann, K., Hadwiger, P., Wagner, E., Solid-phase synthesis of sequence-defined T-, i-, and U-shape polymers for pDNA and siRNA delivery. Angew. Chem. Int. Ed. 50 (2011), 8986–8989.
106. [106] Endres, T.K., Beck-Broichsitter, M., Samsonova, O., Renette, T., Kissel, T.H., Self-assembled biodegradable amphiphilic PEG-PCL-lPEI triblock copolymers at the borderline between micelles and nanoparticles designed for drug and gene delivery. Biomaterials 32 (2011), 7721–7731.
107. [107] Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K.W., Song, E.-W., Wang, J., Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano 5 (2011), 1483–1494.
108. [108] Yu, H., Zou, Y., Wang, Y., Huang, X., Huang, G., Sumer, B.D., Boothman, D.A., Gao, J., Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery. ACS Nano 5 (2011), 9246–9255.
109. [109] Kim, H.J., Ishii, A., Miyata, K., Lee, Y., Wu, S., Oba, M., Nishiyama, N., Kataoka, K., Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown. J. Control. Release 145 (2010), 141–148.
110. [110] Philipp, A., Zhao, X., Tarcha, P., Wagner, E., Zintchenko, A., Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. Bioconjug. Chem. 20 (2009), 2055–2061.
111. [111] Kim, H.J., Oba, M., Pittella, F., Nomoto, T., Cabral, H., Matsumoto, Y., Miyata, K., Nishiyama, N., Kataoka, K., PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous BxPC3 pancreatic tumor. J. Drug Target. 20 (2012), 33–42.
112. [112] Kim, H.J., Ishii, T., Zheng, M., Watanabe, S., Toh, K., Matsumoto, Y., Nishiyama, N., Miyata, K., Kataoka, K., Multifunctional polyion complex micelle featuring enhanced stability, targetability, and endosome escapability for systemic siRNA delivery to subcutaneous model of lung cancer. Drug Deliv. Transl. Res. 4 (2014), 50–60.
113. [113] Kim, H.J., Miyata, K., Nomoto, T., Zheng, M., Kim, A., Liu, X., Cabral, H., Christie, R.J., Nishiyama, N., Kataoka, K., siRNA delivery from triblock copolymer micelles with spatially-ordered compartments of PEG shell, siRNA-loaded intermediate layer, and hydrophobic core. Biomaterials 35 (2014), 4548–4556.
114. [114] Yagi, N., Manabe, I., Tottori, T., Ishihara, A., Ogata, F., Kim, J.H., Nishimura, S., Fujiu, K., Oishi, Y., Itaka, K., Kato, Y., Yamauchi, M., Nagai, R., A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res. 69 (2009), 6531–6538.
115. [115] Mui, B.L., Tam, Y.K., Jayaraman, M., Ansell, S.M., Du, X., Tam, Y.Y.C., Lin, P.J.C., Chen, S., Narayanannair, J.K., Rajeev, K.G., Manoharan, M., Akinc, A., Maier, M.A., Cullis, P., Madden, T.D., Hope, M.J., Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol. Ther. Nucleic Acids, 2, 2013, e139.
116. [116] Sun, Q., Kang, Z., Xue, L., Shang, Y., Su, Z., Sun, H., Ping, Q., Mo, R., Zhang, C., A collaborative assembly strategy for tumor-targeted siRNA delivery. J. Am. Chem. Soc. 137 (2015), 6000–6010.
117. [117] Hansen, J.M., Harris, C., Glutathione during embryonic development. Biochim. Biophys. Acta, 2014 (Epub ahead of print).
118. [118] Circu, M.L., Aw, T.Y., Glutathione and modulation of cell apoptosis. Biochim. Biophys. Acta 1823 (2012), 1767–1777.
119. [119] Smeyne, M., Smeyne, R.J., Glutathione metabolism and Parkinson's disease. Free Radic. Biol. Med. 62 (2013), 13–25.
120. [120] Ryu, J.H., Chacko, R.T., Jiwpanich, S., Bickerton, S., Babu, R.P., Thayumanavan, S., J. Am. Chem. Soc. 132 (2010), 17227–17235.
121. [121] Matsumoto, S., Christie, R.J., Nishiyama, N., Miyata, K., Ishii, A., Oba, M., Koyama, H., Yamasaki, Y., Kataoka, K., Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery. Biomacromolecules 10 (2009), 119–127.
122. [122] Oe, Y., Christie, R.J., Naito, M., Low, S.A., Fukushima, S., Toh, K., Miura, Y., Matsumoto, Y., Nishiyama, N., Miyata, K., Kataoka, K., Actively-targeted polyion complex micelles stabilized by cholesterol and disulfide cross-linking for systemic delivery of siRNA to solid tumors. Biomaterials 35 (2014), 7887–7895.
123. [123] Rozema, D.B., Lewis, D.L., Wakefield, D.H., Wong, S.C., Klein, J.J., Roesch, P.L., Bertin, S.L., Reppen, T.W., Chu, Q., Blokhin, A.V., Hagstrom, J.E., Wolff, J.A., Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 12982–12987.
124. [124] Gish, R.G., Yuen, M.-F., Chan, H.L.Y., Given, B.D., Lai, C.–.L., Locarnini, S.A., Lau, J.Y.N., Wooddell, C.I., Schluep, T., Lewis, D.L., Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antivir. Res. 121 (2015), 97–108.
125. [125] Stauber, T., Jentsch, T.J., Chloride in vesicular trafficking and function. Annu. Rev. Physiol. 75 (2013), 453–477.
126. [126] Murthy, N., Thng, Y.X., Schuck, S., Xu, M.C., Fréchet, J.M.J., A novel strategy for encapsulation and release of proteins: hydrogels and microgels with acid-labile acetal cross-linkers. J. Am. Chem. Soc. 124 (2002), 12398–12399.
127. [127] Bae, Y., Fukushima, S., Harada, A., Kataoka, K., Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. 42 (2003), 4640–4643.
128. [128] Oishi, M., Nagasaki, Y., Itaka, K., Nishiyama, N., Kataoka, K., Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 127 (2005), 1624–1625.
129. [129] Jeong, J.H., Kim, S.W., Park, T.G., Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug. Chem. 14 (2003), 473–479.
130. [130] Heller, J., Barr, J., Ng, S.Y., Abdellauoi, K.S., Gurny, R., Poly(ortho esters): synthesis, characterization, properties and uses. Adv. Drug Deliv. Rev. 54 (2002), 1015–1039.
131. [131] Lee, Y., Fukushima, S., Bae, Y., Hiki, S., Ishii, T., Kataoka, K., A protein nanocarrier from charge-conversion polymer in response to endosomal pH. J. Am. Chem. Soc. 129 (2007), 5362–5363.
132. [132] Lee, Y., Ishii, T., Cabral, H., Kim, H.J., Seo, J.H., Nishiyama, N., Oshima, H., Osada, K., Kataoka, K., Charge-conversional polyionic complex micelles—efficient nanocarriers for protein delivery into cytoplasm. Angew. Chem. Int. Ed. 48 (2009), 5309–5312.
133. [133] Shim, M.S., Kwon, Y.J., Acid-responsive linear polyethyleneimine for efficient, specific, and biocompatible siRNA delivery. Bioconjug. Chem. 20 (2009), 488–499.
134. [134] Takemoto, H., Miyata, K., Hattori, S., Ishii, T., Suma, T., Uchida, S., Nishiyama, N., Kataoka, K., Acidic pH-responsive siRNA conjugate for reversible carrier stability and accelerated endosomal escape with reduced IFNα-associated immune response. Angew. Chem. Int. Ed. 52 (2013), 6218–6221.
135. [135] Kulkarni, A., DeFrees, K., Hyun, S.-H., Tompson, D.H., Pendant polyer:amino-β-cyclodextrin:siRNA guest:host nanoparticles as efficient vectors for gene silencing. J. Am. Chem. Soc. 134 (2012), 7596–7599.
136. [136] Nie, Y., Günther, M., Gu, Z., Wagner, E., Pyridylhydrazone-based PEGylation for pH-reversible lipopolyplex shielding. Biomaterials 32 (2011), 858–869.
137. [137] Yang, X.Z., Du, J.Z., Dou, S., Mao, C.Q., Long, H.Y., Wang, J., Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano 6 (2012), 771–781.
138. [138] Gorman, M.W., Feigl, E.O., Buffington, C.W., Human plasma ATP concentration. Clin. Chem. 53 (2007), 318–325.
139. [139] Naito, M., Ishii, T., Matsumoto, A., Miyata, K., Miyahara, Y., Kataoka, K., A phenylboronate-functionalized polyion complex micelle for ATP-triggered release of siRNA. Angew. Chem. Int. Ed. 51 (2012), 1–6.
140. [140] Mo, R., Jiang, T., DiSanto, R., Tai, W., Gu, Z., ATP-triggered anticancer drug delivery. Nat. Commun., 5, 2014, 3364.
141. [141] Mo, R., Jiang, T., Gu, Z., Enhanced anticancer efficacy by ATP-mediated liposomal drug delivery. Angew. Chem. 126 (2014), 5925–5930.
142. [142] Quail, D.F., Joyce, J.A., Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19 (2013), 1423–1437.
143. [143] Neri, D., Supuran, C.T., Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 10 (2011), 767–777.
144. [144] Li, J., Yu, X., Wang, Y., Yuan, Y., Xiao, H., Cheng, D., Shuai, X., A reduction and pH dual-sensitive polymeric vector for long-circulating and tumor-targeted siRNA delivery. Adv. Mater. 26 (2014), 8217–8224.
145. [145] Hama, S., Itakura, S., Nakai, M., Nakayama, K., Morimoto, S., Suzuki, S., Kogure, K., Overcoming the polyethylene glycol dilemma via pathological environment-sensitive change of the surface property of nanoparticles for cellular entry. J. Control. Release 206 (2015), 67–74.
146. [146] Wang, H.-X., Yang, X.-Z., Sun, C.-Y., Mao, C.-Q., Zhu, Y.-H., Wang, J., Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 35 (2014), 7622–7634.
147. [147] Shuman Moss, L.A., Jensen-Taubman, S., Stetler-Stevenson, W.G., Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am. J. Pathol. 181 (2012), 1895–1899.
148. [148] Decock, J., Thirkettle, S., Wagstaff, L., Edwards, D.R., Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med. 6 (2011), 1254–1265.
149. [149] Kessenbrock, K., Plaks, V., Werb, Z., Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141 (2010), 52–67.
150. [150] Li, H., Yu, S.S., Miteva, M., Nelson, C.E., Werfel, T., Giorgio, T.D., Duvall, C.L., Matrix metalloproteinase responsive, proximity-activated polymeric nanoparticles for siRNA delivery. Adv. Funct. Mater. 23 (2013), 3040–3052.
151. [151] Li, H., Miteva, M., Kirkbride, K.C., Cheng, M.J., Nelson, C.E., Simpson, E.M., Gupta, M.K., Duvall, C.L., Giorgio, T.D., Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery. Biomacromolecules 16 (2015), 192–201.
152. [152] Hatakeyama, H., Akita, H., Ito, E., Hayashi, Y., Oishi, M., Nagasaki, Y., Danev, R., Nagayama, K., Kaji, N., Kukuchi, H., Baba, Y., Harashima, H., Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 32 (2011), 4306–4316.
153. [153] Zhu, L., Wang, T., Perche, F., Taigind, A., Torchilin, V.P., Enhanced anticancer acitivty of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 17047–17052.
154. [154] Huang, S., Shao, K., Kuang, Y., Liu, Y., Li, J., An, S., Guo, Y., Ma, H., He, X., Jiang, C., Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials 34 (2013), 5294–5302.
155. [155] van Rijt, S.H., Bölükbas, D.A., Argyo, C., Datz, S., Lindner, M., Eickelberg, O., Königshoff, M., Bein, T., Meiners, S., Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors. ACS Nano 9 (2015), 2377–2389.
156. [156] Le, J., Ge, Z., Liu, S., PEG-sheddable polyplex micelles as smart gene carriers based on MMP-cleavable peptide-linked block copolymers. Chem. Commun. 49 (2013), 6974–6976.
157. [157] Gao, W., Xiang, B., Meng, T.-T., Liu, F., Qi, X.–.R., Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials 34 (2013), 4137–4149.
158. [158] Nair, J.K., Willoughby, J.L.S., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'in, A.V., Milstein, S., Taneja, N., O′Shea, J., Shaikh, S., Zhang, L., van der Sluis, R.J., Jung, M.E., Akinc, A., Hutabarat, R., Kuchimanchi, S., Fitzgerald, K., Zimmermann, T., van Berkel, T.J.C., Maier, M.A., Rajeev, K.G., Manoharan, M., Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136 (2014), 16958–16961.
159. [159] Zern, B.J., Chacko, A.-M., Liu, J., Greineder, C.F., Blankemeyer, E.R., Radhakrishnan, R., Muzykantov, V., Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PEG detection of pulmonary inflammation. ACS Nano 7 (2013), 2461–2469.
160. [160] Cruz, L.J., Tacken, P.J., Fokkink, R., Figdor, C.G., The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 32 (2011), 6791–6803.
161. [161] Stefanick, J.F., Ashley, J.D., Kiziltepe, T., Bilgicer, B., A systemic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. ACS Nano 7 (2013), 2935–2947.
162. [162] Hak, S., Helgesen, E., Hektoen, H.H., Huuse, E.M., Jarzyna, P.A., Mulder, W.J., Haraldseth, O., de L. Davies, C., The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano 6 (2012), 5648–5658.
163. [163] Sykes, E.A., Chen, J., Zheng, G., Chan, W., Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano 8 (2014), 5696–5706.
164. [164] Wolfrum, C., Shi, S., Jayaprakash, K.N., Jayaraman, M., Wang, G., Pandey, F.K., Rajeev, K.G., Nakayama, T., Charrise, K., Ndungo, E.M., Zimmermann, T., Koteliansky, V., Manoharan, M., Stoffel, M., Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25 (2007), 1149–1157.
165. [165] Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R.K., Racie, T., Rajeev, K.G., Röhl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., Vornlocher, H.-P., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004), 173–178.
166. [166] Khan, O.F., Zaia, E.W., Yin, H., Bogorad, R.L., Pelet, J.M., Webber, M.J., Zhuang, I., Dahlman, J.E., Langer, R., Anderson, D.G., Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo. Angew. Chem. Int. Ed. 53 (2014), 1–6.
167. [167] Smits, R.G., Koper, G.J.M., Mandel, M., The influence of nearest- and next-neearest-neighbor interactions on the potentiometric titration of linear poly(ethylenimine). J. Phys. Chem. 97 (1993), 5745–5751.
168. [168] Lee, Y., Mo, H., Koo, H., Park, J.Y., Cho, M.Y., Jin, G.W., Park, J.S., Visualization of the degradation of a disulfide polymer, linear poly(ethylenimine sulfide), for gene delivery. Bioconjug. Chem. 18 (2007), 13–18.
169. [169] Gosselin, M.A., Guo, W., Lee, R.J., Efficient gene transfer using reversible cross-linked low molecular weight polyethylenimine. Bioconjug. Chem. 12 (2001), 989–994.
170. [170] Uchida, H., Miyata, K., Oba, M., Ishii, T., Suma, T., Itaka, K., Nishiyama, N., Kataoka, K., Odd-even effect of repeating aminoethylene units in the side chain of N-substituted polyaspartamides on gene transfection profiles. J. Am. Chem. Soc. 133 (2011), 15524–15532.
171. [171] Pittella, F., Miyata, K., Maeda, Y., Suma, T., Watanabe, S., Chen, Q., Christie, R.J., Osada, K., Nishiyama, N., Kataoka, K., Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles. J. Control. Release 161 (2012), 868–874.
172. [172] Convertine, A.J., Benoit, D.S.W., Duvall, C.L., Hoffman, A.S., Stayton, P.S., Development of a novel endosomolytic diblock copolymer for siRNA delivery. J. Control. Release 133 (2009), 221–229.
173. [173] Midoux, P., Pichon, C., Yaouanc, J.J., Jaffrés, P.A., Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol. 157 (2009), 166–178.
174. [174] Dahlman, J.E., Barnes, C., Khan, O.F., Thiriot, A., Jhunjunwala, S., Shaw, T.E., Xing, Y., Sager, H.B., Sahay, G., Speciner, L., Bader, A., Bogorad, R.L., Yin, H., Racie, T., Dong, Y., Jiang, S., Seedorf, D., Dave, A., Sandhu, K.S., Webber, M.J., Novobrantseva, T., Ruda, V.M., Lytton-Jean, A.K.R., Levins, C.G., Kalish, B., Mudge, D.K., Perez, M., Abezgauz, L., Dutta, P., Smith, L., Charisse, K., Kieran, M.W., Fitzgerald, K., Nahrendorf, M., Danino, D., Tuder, R.M., von Andrian, U.H., Akinc, A., Panigrahy, D., Schroeder, A., Koteliansky, V., Langer, R., Anderson, D.G., In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Biotechnol. 9 (2014), 648–655.
175. [175] Perche, F., Biswas, S., Wang, T., Zhu, L., Torchilin, V.P., Hypoxia-targeted siRNA delivery. Angew. Chem. Int. Ed. 53 (2014), 3362–3366.
176. [176] Xu, Y., Szoka, F.C. Jr., Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35 (1996), 5616–5623.
177. [177] Hatakeyama, H., Akita, H., Harashima, H., A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev. 63 (2011), 152–160.
178. [178] Hafez, I.M., Maurer, N., Cullis, P.R., On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8 (2001), 1188–1196.
179. [179] Ashley, C.E., Carnes, E.C., Epler, K.E., Padilla, D.P., Phillips, G.K., Castillo, R.E., Wilkinson, D.C., Wilkinson, B.S., Burgard, C.A., Kalinich, R.M., Townson, J.L., Chackerian, B., Willman, C.L., Peabody, D.S., Wharton, W., Brinker, C.J., Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano 6 (2012), 2174–2188.
180. [180] Elbakry, A., Zaky, A., Liebl, R., Rachel, R., Geopferich, A., Breunig, M., Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett. 9 (2009), 2059–2064.
181. [181] Lee, S.K., Tung, C.-H., A Fabricated siRNA nanoparticle for ultralong gene silencing in vivo. Adv. Funct. Mater. 23 (2013), 3488–3493.
182. [182] Deng, Z.J., Morton, S.W., Ben-Akiva, E., Dreaden, E.C., Shopsowitz, K.E., Hammond, P.T., Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 7 (2013), 9571–9584.
183. [183] Coley, H.M., Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev. 34 (2008), 378–390.
184. [184] Taheri, M., Mahjoubi, F., MRP1 but not MDR1 is associated with response to neoadjuvant chemotherapy in breast cancer patients. Dis. Markers 34 (2013), 387–393.
185. [185] Gandhi, N.S., Tekade, R.K., Chougule, M.B., Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J. Control. Release 194 (2014), 238–256.
186. [186] Suma, T., Miyata, K., Anraku, Y., Watanabe, S., Christie, R.J., Takemoto, H., Shioyama, M., Gouda, N., Ishii, T., Nishiyama, N., Kataoka, K., Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycations, and detachable PEG. ACS Nano 6 (2012), 6693–6705.
187. [187] Kakizawa, Y., Furukawa, S., Ishii, A., Kataoka, K., Organic–inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J. Control. Release 111 (2006), 368–370.
188. [188] Pittella, F., Zhang, M., Lee, Y., Kim, H.J., Tockary, T., Osada, K., Ishii, T., Miyata, K., Nishiyama, N., Kataoka, K., Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials 32 (2011), 3106–3114.
189. [189] Yamaguchi, M., Regulatory role of regucalcin in heart calcium signaling: insight into cardiac failure (Review). Biomed. Rep. 2 (2014), 303–308.
190. [190] Li, J., Chen, Y.-C., Tseng, Y.-C., Mozumdar, S., Huang, L., Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release 142 (2010), 416–421.
191. [191] Yang, Y., Li, J., Liu, F., Huang, L., Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol. Ther. 20 (2012), 609–615.
192. [192] Jensen, S.A., Day, E.S., Ko, C.H., Hurley, L.A., Luciano, J.P., Kouri, F.M., Merkel, T.J., Luthi, A.J., Patel, P.C., Cutler, J.I., Daniel, W.L., Scott, A.W., Rotz, M.W., Meade, T.J., Giljohann, D.A., Mirkin, C.A., Stegh, A.H., Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci. Transl. Med., 5, 2013, 209ra152.
193. [193] Kim, H.J., Takemoto, H., Yi, Y., Zheng, M., Maeda, Y., Chaya, H., Hayashi, K., Mi, P., Pittella, F., Christie, R.J., Toh, K., Matsumoto, Y., Nishiyama, N., Miyata, K., Kataoka, K., Precise engineering of siRNA delivery vehicles to tumors using polyion complexes and gold nanoparticles. ACS Nano 8 (2014), 8979–8991.
194. [194] Shimizu, H., Hori, Y., Kaname, S., Yamada, K., Nishiyama, N., Matsumoto, S., Miyata, K., Oba, M., Yadama, A., Kataoka, K., Fujita, T., siRNA-based therapy ameliorates glomerulonephritis. J. Am. Soc. Nephrol. 21 (2010), 622–633.
195. [195] Sizovs, A., Song, X., Waxham, M.N., Jia, Y., Feng, F., Chen, J., Wicker, A.C., Xu, J., Yu, Y., Wang, J., Precisely tunable engineering of sub-30 nm monodisperse oligonucleotide nanoparticles. J. Am. Chem. Soc. 136 (2014), 234–240.
196. [196] Dohmen, C., Edinger, D., Fröhlich, T., Schreiner, L., Lächelt, U., Troiber, C., Rädler, J., Hadwiger, P., Vornlocher, H., Wagner, E., Nanosized multifunctional polyplexes for receptor-mediated siRNA delivery. ACS Nano 6 (2012), 5198–5208.